Medicare’s Policy on Alzheimer’s Drugs Comes Under Fire at House Hearing
WASHINGTON — House members on both sides of the aisle were in surprising agreement on a number of healthcare issues Wednesday, most notably the need for Medicare to reconsider its coverage decision on amyloid-inhibiting Alzheimer’s drugs such as aducanumab (Aduhelm) and lecanemab (Leqembi). “There’s been a lot of attention to a decision by CMS [the […]